ZA896287B - Pharmaceutical combination preparations for use in anti-neoplastic therapy - Google Patents

Pharmaceutical combination preparations for use in anti-neoplastic therapy

Info

Publication number
ZA896287B
ZA896287B ZA896287A ZA896287A ZA896287B ZA 896287 B ZA896287 B ZA 896287B ZA 896287 A ZA896287 A ZA 896287A ZA 896287 A ZA896287 A ZA 896287A ZA 896287 B ZA896287 B ZA 896287B
Authority
ZA
South Africa
Prior art keywords
pharmaceutical combination
combination preparations
neoplastic therapy
compounds
therapy
Prior art date
Application number
ZA896287A
Other languages
English (en)
Inventor
Hans Hermann Prof Grunicke
Hermann Grunicke Prof Hans
Dieter Dr Herrmann
Herrmann Dr Dieter
Johann Dr Hofmann
Hofmann Dr Johann
Elmar Dr Bosies
Bosies Dr Elmar
Original Assignee
Boehringer Mannheim Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6361067&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA896287(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Mannheim Gmbh filed Critical Boehringer Mannheim Gmbh
Publication of ZA896287B publication Critical patent/ZA896287B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0489—Phosphates or phosphonates, e.g. bone-seeking phosphonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Plant Substances (AREA)
ZA896287A 1988-08-18 1989-08-17 Pharmaceutical combination preparations for use in anti-neoplastic therapy ZA896287B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3827974A DE3827974A1 (de) 1988-08-18 1988-08-18 Kombinationspraeparate von proteinkinase-c-inhibitoren mit lipiden, lipid-analoga, cytostatica oder inhibitoren von phospholipasen

Publications (1)

Publication Number Publication Date
ZA896287B true ZA896287B (en) 1990-05-30

Family

ID=6361067

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA896287A ZA896287B (en) 1988-08-18 1989-08-17 Pharmaceutical combination preparations for use in anti-neoplastic therapy

Country Status (17)

Country Link
US (2) US5578590A (xx)
EP (1) EP0359981B1 (xx)
JP (1) JPH02108636A (xx)
KR (1) KR900002784A (xx)
AT (1) ATE91903T1 (xx)
AU (1) AU627207B2 (xx)
CA (1) CA1330035C (xx)
DD (1) DD283938A5 (xx)
DE (2) DE3827974A1 (xx)
DK (1) DK401089A (xx)
ES (1) ES2058420T3 (xx)
HU (1) HUT52396A (xx)
IE (1) IE64635B1 (xx)
IL (1) IL91343A (xx)
NZ (1) NZ230323A (xx)
PT (1) PT91470A (xx)
ZA (1) ZA896287B (xx)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA908936B (en) * 1989-11-13 1991-09-25 Merrell Dow Pharma Treatment of multi-drug resistant tumors with quinolyloxazole-2-ones
ZA908852B (en) * 1989-11-13 1991-09-25 Merrell Dow Pharma Treatment of multi-drug resistant tumors with pyridyloxazole-2-ones
EP0507938A4 (en) * 1990-11-02 1993-03-10 Sphinx Pharmaceuticals Corporation Bis-(hydroxyalkylamino)-anthraquinone inhibitors of protein kinase c
US5141957A (en) * 1990-11-02 1992-08-25 Sphinx Pharmaceuticals Corporation 1,4-bis-(amino-hydroxyalkylamino)-anthraquinones for inhibiting protein kinase c
US5204370A (en) * 1990-11-05 1993-04-20 Sphinx Pharmaceuticals Corporation Bis-(hydroxyalkylamino)-anthraquinone inhibitors of protein kinase C
DE69221069T2 (de) * 1991-05-14 1997-11-13 Merrell Pharma Inc Hemmung von metastasen bei krebspatienten mit pyridyloxazol-2-onen
WO1993002209A1 (en) * 1991-07-22 1993-02-04 The Regents Of The University Of California Methods of designing specific affectors using three-dimensional conformation of enzyme/affector complex
US5216014A (en) * 1991-09-10 1993-06-01 Sphinx Pharmaceuticals Corporation Furo-coumarinsulfonamides as protein kinase C inhibitors
GB9126209D0 (en) * 1991-12-10 1992-02-12 Orion Yhtymae Oy Drug formulations for parenteral use
US5270310A (en) * 1991-12-13 1993-12-14 Sphinx Pharmaceuticals Corporation N-aminoalkyl amide inhibitors of protein kinase C
US5292737A (en) * 1992-10-23 1994-03-08 Sphinx Pharmaceuticals Corporation N,N'-bis(sulfonamido)-2-amino-4-iminonaphthalen-1-ones and N,N'-bis(amido)-2-amino-4-iminonaphthalen-1-ones
US5844001A (en) * 1993-02-26 1998-12-01 Research Development Foundation Combination platinum chemotherapeutic/antiestrogen therapy for human cancers
ZA941290B (en) * 1993-02-26 1995-08-25 Res Dev Foundation Combination cisplatin/tamoxifen therapy for human cancers
EP0643966A4 (en) * 1993-03-03 1995-08-09 Kyowa Hakko Kogyo Kk SENSITIVITY BOOSTER FOR ANTINEOPLASTIC AGENT.
GB9509572D0 (en) * 1995-05-11 1995-07-05 Cancer Res Campaign Tech Cancer therapy
US6274576B1 (en) 1995-06-27 2001-08-14 The Henry Jackson Foundation For The Advancement Of Military Medicine Method of dynamic retardation of cell cycle kinetics to potentiate cell damage
WO1997001344A2 (en) * 1995-06-27 1997-01-16 Henry M. Jackson Foundation For The Advancement Of Military Medicine Method of dynamic retardation of cell cycle kinetics to potentiate cell damage
US5744460A (en) * 1996-03-07 1998-04-28 Novartis Corporation Combination for treatment of proliferative diseases
US6232299B1 (en) * 1996-05-01 2001-05-15 Eli Lilly And Company Use of protein kinase C inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy
US6063814A (en) * 1997-04-14 2000-05-16 Chang; Richard L. Phorbol esters as anti-neoplastic and white blood cell elevating agents
EP1053243B1 (en) * 1998-02-12 2011-03-30 Emory University Sphingolipid derivatives and their methods of use
JP3565003B2 (ja) 1998-04-02 2004-09-15 日産自動車株式会社 自動車の排水構造
DE19959689A1 (de) * 1998-12-04 2000-06-08 Max Delbrueck Centrum Mittel zur Tumortherapie
WO2001024763A2 (en) 1999-10-01 2001-04-12 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
AUPQ641100A0 (en) * 2000-03-23 2000-04-15 Australia Nuclear Science & Technology Organisation Methods of synthesis and use of radiolabelled platinum chemotherapeutic ag ents
AU2001271257A1 (en) * 2000-06-29 2002-01-14 Eli Lilly And Company Use of a protein kinase c inhibitor to enhance the clinical efficacy of anti-neoplastic chemotherapeutic agents and radiation therapy
US6569853B1 (en) * 2000-11-06 2003-05-27 Combinatorx, Incorporated Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders
US6693125B2 (en) * 2001-01-24 2004-02-17 Combinatorx Incorporated Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders
US20050065205A1 (en) 2002-03-07 2005-03-24 Daniel Alkon Methods for Alzheimer's disease treatment and cognitive enhance
US6825229B2 (en) 2002-03-07 2004-11-30 Blanchette Rockefeller Neurosciences Institute Methods for Alzheimer's Disease treatment and cognitive enhancement
US20080004332A1 (en) * 2002-03-07 2008-01-03 Alkon Daniel L Methods for alzheimer's disease treatment and cognitive enhancement
CA2492059A1 (en) * 2002-07-11 2004-01-22 Combinatorx, Incorporated Combinations of drugs for the treatment of neoplasms
AU2003258061A1 (en) * 2002-08-02 2004-02-23 Salmedix, Inc. Therapeutic inhibitionof protein kinases in cancer cells
US20040175384A1 (en) * 2003-12-12 2004-09-09 Mohapatra Shyam S. Protein kinase C as a target for the treatment of respiratory syncytial virus
US20050080075A1 (en) * 2003-08-25 2005-04-14 Nichols M. James Formulations, conjugates, and combinations of drugs for the treatment of neoplasms
US20050100508A1 (en) * 2003-11-12 2005-05-12 Nichols M. J. Methods for identifying drug combinations for the treatment of proliferative diseases
US20050158320A1 (en) * 2003-11-12 2005-07-21 Nichols M. J. Combinations for the treatment of proliferative diseases
US8592368B2 (en) 2003-12-19 2013-11-26 University Of South Florida JAK/STAT inhibitors and MAPK/ERK inhibitors for RSV infection
TW201207390A (en) 2004-05-18 2012-02-16 Brni Neurosciences Inst Method for screening agent for antidepressant activity
DK2447252T3 (da) * 2004-05-23 2020-03-16 Hmi Medical Innovations Llc Theramuteinmodulatorer
ES2246165B1 (es) * 2004-07-20 2006-12-01 Universitat De Valencia Uso combinado del pteroestilbeno y la quercetina para la fabricacion de medicamentos utiles en el tratamiento del cancer.
US8431110B2 (en) * 2005-05-23 2013-04-30 Hmi Medical Innovations, Llc. Compounds and method of identifying, synthesizing, optimizing and profiling protein modulators
KR101347100B1 (ko) 2005-07-29 2014-01-03 블랜체트 록펠러 뉴로사이언시즈 인스티튜트 단독의 또는 ｐｋｃ 억제제와 배합된 ｐｋｃ 활성화제의 장기 기억 향상을 위한 용도
US20070112053A1 (en) 2005-09-16 2007-05-17 Pickett Cecil B Pharmaceutical compositions and methods using temozolomide and a protein kinase inhibitor
CN103789389B (zh) * 2005-11-23 2017-01-04 杰勒德·M·豪斯 鉴定、合成、优化和表征蛋白调节剂的化合物和方法
EP2091520B1 (en) * 2006-11-10 2012-02-22 Alphaptose Gmbh Oral dosage form comprising tri-substituted glycerol compounds
JP5512275B2 (ja) * 2006-11-10 2014-06-04 ラディオプロテクト アルファプトーゼ ウーゲー（ハフツングスベシュレンクト） ウント コー．カーゲー 放射線傷害治療のための三置換グリセロール化合物の使用
EP3332797A3 (en) 2007-02-09 2018-08-01 Blanchette Rockefeller Neurosciences Institute Therapeutic effects of bryostatins, bryologs and other related substances on head trauma-induced memory impairment and brain injury
CA2952953C (en) * 2014-06-19 2024-01-23 Quercegen Pharmaceuticals Llc Method for treating cancer with a combination of quercetin and a chemotherapy agent
WO2019169389A1 (en) * 2018-03-02 2019-09-06 Epicentrx, Inc. Methods and compositions for treating cancer and sensitizing tumor cells to kinase inhibitors
US11872241B2 (en) 2018-11-30 2024-01-16 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for reducing major thrombotic events in cancer patients
GB202014831D0 (en) 2020-09-21 2020-11-04 Dc Europa Ltd Disconnection agents

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1984001506A1 (en) * 1982-10-13 1984-04-26 Univ Birmingham Pharmaceutical preparations for use in antitumour therapy
EP0409845A4 (en) * 1988-02-23 1991-07-03 U.S. Bioscience Method for protection from chemotherapeutic side effects
GB8813682D0 (en) * 1988-06-09 1988-07-13 Reckitt & Colmann Prod Ltd Pharmaceutical compositions

Also Published As

Publication number Publication date
EP0359981A1 (de) 1990-03-28
DE3827974A1 (de) 1990-02-22
IL91343A0 (en) 1990-03-19
PT91470A (pt) 1990-03-08
JPH02108636A (ja) 1990-04-20
KR900002784A (ko) 1990-03-23
DE58905028D1 (de) 1993-09-02
DD283938A5 (de) 1990-10-31
AU627207B2 (en) 1992-08-20
IL91343A (en) 1996-05-14
EP0359981B1 (de) 1993-07-28
US5578590A (en) 1996-11-26
IE892646L (en) 1990-02-18
IE64635B1 (en) 1995-08-09
DK401089A (da) 1990-02-19
US5770593A (en) 1998-06-23
ATE91903T1 (de) 1993-08-15
NZ230323A (en) 1992-05-26
HUT52396A (en) 1990-07-28
CA1330035C (en) 1994-06-07
AU3955089A (en) 1990-02-22
DK401089D0 (da) 1989-08-15
ES2058420T3 (es) 1994-11-01

Similar Documents

Publication Publication Date Title
IL91343A0 (en) Anti-neoplastic combination preparations
EP0283713A3 (en) Complexes of saponins with phospholipids and pharmaceutical and cosmetic compositions containing them
IT1201149B (it) Complessi di bioflavonoidi con fosfolipidi,loro preparazione,uso e composizioni farmaceutici e cosmetiche
EP0727437A3 (en) PEG-protein adducts
NO179911C (no) Optisk aktivt 5H-pyrrolo[3,4-bÅpyrazinderivat samt farmasöytiske preparater inneholdende derivatet
GB2305107B (en) Biological materials preserved by antioxidant synthetic catalytic free radical scavengers
GR3007202T3 (xx)
WO1987003480A3 (fr) Medicament a effet anti-tumoral contenant de l'hexadecylphosphocholine
NO180584C (no) Bisnaftalimider som inneholder aminosyreavledete linkere, for anvendelse som antikreftmidler, samt farmasöytiske preparater
IL68456A0 (en) Pharmaceutical compositions comprising perfluorohydrocarbons as vehicles
DK13089A (da) Substituerede 5,6,7,8-tetrahydro-4h-thieno-(2,3-d)azepin-forbindelser, fremgangsmaade til fremstilling deraf samt farmaceutiske praeparater indeholdende samme
AU7999787A (en) Active compounds for use in the treatment of tumors
IL87778A (en) Topical pharmaceutical compositions in the form of a hydrogel containing stabilized therapeutically active proteins and their preparation
AU536582B2 (en) Plenylpiperazine derivatives of 1,3,4-oxiadiazolylphends
EP0268135A3 (en) Coccidiocidal agents
CA2003213A1 (en) Antimycotically active cyclopropyl-substituted azolylmethylcarbinols
NO882065D0 (no) Diarylalkyl-substituerte alkylaminer, fremgangsmaate til deres fremstilling, deres anvendelse, samt legemidler som inneholder denne.
NZ230899A (en) A combination preparation as an antidote for blood anticoagulants
EP0316639A3 (en) Azelastin embonate, process for its preparation and pharmaceutical compositions containing azelastin embonate as the active ingredient
EP0265338A3 (en) Stable therapeutical compositions based on hydrophobic vegetable oil, and process for preparing them
IE883402L (en) Azelastine embonate, processes for its preparation and pharmaceutical formulations which contain azelastine embonate as active substance
IT8709514V0 (it) Strumento a siringa per immissione nei piani sottostanti la cute di prodotti farmaceutici.
IT8322410A0 (it) Procedimento per produrre prodotti di gomma per uso medico o farmaceutico.
IT1251993B (it) Composizioni farmaceutiche ad uso orale,a base di esteri di gangliosidi,per il trattamento di neuropatie del sistema nervoso periferico
IT1229202B (it) Gratinatore per la preparazione industriale di piatti pronti preconfezionati in vaschetta.